TGA Issues Infringement Notices to Prime Medic Group Over Weight Loss Medicine Advertising
02 Feb 2026
An individual for allegedly advertising weight loss medicines in breach of the Therapeutic Goods Act 1989.
-
Prime Medic received a notice for $19,800.
-
The individual received a notice for $3,960.
-
Both parties paid their infringement notices in January 2026.
Prime Medic operates an online telehealth platform offering doctor consultations. It is alleged that between January and July 2025, the company advertised prescription-only weight loss medicines, including Ozempic and Mounjaro, directly to consumers.
Under the Act, prescription medicines cannot be advertised directly to the public, as this may create inappropriate demand and undermine the patient-health professional relationship. Treatment decisions should always be made in consultation with a qualified health practitioner.
The advertising is also alleged to have included claims about treating serious conditions, which are considered restricted or prohibited representations. Such claims are not allowed in therapeutic goods advertising unless TGA approval has been obtained.
The TGA reminds health providers to understand their legal obligations before advertising therapeutic goods. Serious breaches of the Act may result in regulatory action, including infringement notices, prevention or direction notices, or civil or criminal proceedings.
Source: Therapeutic Goods Administration (TGA)
